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Abstract
Despite the availability of highly effective therapy for hepatitis C virus (HCV) infection, few
patients receive treatment. Barriers arising at multiple levels, from diagnosis to specialist referral,
may impede the delivery of hepatitis C care. At the patient level, lack of awareness, fear of side
effects, poor adherence, and comorbid conditions may prevent treatment. For providers, limited
knowledge, lack of availability, and communication difficulties may be problematic. At the
government and payer level, a lack of promotion, surveillance, and funding may interfere. Each of
these barriers needs to be addressed if wider implementation of antiviral therapy is to be achieved.
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Recent advances in the treatment of hepatitis C virus (HCV) infection have produced
antiviral therapies capable of higher cure rates and shorter treatment durations. For the 130
million to 170 million persons worldwide with chronic HCV infection, current therapies
offer a greater than 60% likelihood of sustained virologic response (SVR), regardless of
viral genotype.2-5 However, for effective therapy to be delivered, long-standing barriers to
treatment need to be addressed. Furthermore, with increased costs, higher rates of adverse
events, and complicated treatment algorithms, newer agents may present even greater
challenges to patients and physicians. An understanding of existing barriers to HCV
treatment is important to help guide initiatives aimed at improving treatment rates and,
ultimately, outcomes.
Establishing Current Treatment Rates
Only a small minority of HCV-infected persons receives treatment. The proportion
ofpatients treated with antiviral therapy has been estimated in academic, community, and
VeteransAffairs (VA) hepatitis C cohorts (Table). Treatment rates ranged from 1.1% in a
Vancouver inner-city population to30% at a university-affiliated VA.6,7 Market research
from the United States suggests that lessthan 10% of persons with known infection have
been treated.8 Likewise, market uptake of interferon (IFN) in Europe indicates anaverage
treatment rate of 3.5%.9 Treatment rates may be higher among countries where government-
sponsored surveillance and treatment programs are available, such as in France and other
European countries 10,11.
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Numerous barriers related to patient, provider, government, and payer factors may
effectively prevent the delivery of HCV care. These barriers arise at multiple points
beginning from the time of infection to the delivery of antiviral therapy (Figure).
Patient Factors
Patient-related factors are a common source of treatment deferral and include limited
awareness, poor adherence to physician recommendations, economic or social pressures,
treatment fears, psychiatric disease, and injection drug use.
Knowledge and Awareness
Between 65% and 75% of patients with chronic HCV infection are unaware of their
infection,12 representing the single greatest barrier to treatment. Further, among infected or
at-risk persons, knowledge related to HCV is poor. Confusion regarding modes of
transmission, disease complications, and interpretation of HCV screening tests is
common.13-15 These deficiencies may contribute to missed treatment opportunities,
continued transmission, and poorer health outcomes.12
Non-adherence
Though identification of infection may represent the largest barrier to treatment initiation,
patients frequently fail to seek treatment once the diagnosis is established. Among patients
referred for evaluation of HCV, between 24% and 57% will not attend their initial
subspecialty evaluation.16-18 Likewise, patients may demonstrate a lack of adherence to the
subsequent evaluation process, missing clinic appointments and failing to obtain
recommended diagnostic testing.19 This finding is recognized by treating physicians, 80% of
whom cited patient non-adherence as a barrier to high-quality service in the United
Kingdom (UK).20 There are multiple reasons for this lack of adherence. Notably, patients
may not recognize the urgency to treat an essentially asymptomatic disease.21 Furthermore,
significant economic and social pressures may contribute.
Economic and Social Pressures
Persons with HCV are more likely to be uninsured compared to individuals without HCV.
Data from the National Health and Nutrition Examination Survey (NHANES III) indicate
that 29.6% of HCV-infected patients in the United States are uninsured, compared to 12.2%
of persons without infection.22 Further, uninsured persons are less likely to have contact
with a healthcare professional, reducing the likelihood of diagnosis and treatment. Though a
lack of health insurance is a major barrier to treatment, economic pressures are not exclusive
to the uninsured. A cross-sectional study of HCV patients referred to a tertiary care center
found that one-half of patients cited personal financial resources as a barrier to care, despite
90% of patients possessing medical coverage.23 Fears of missed work obligations may
further contribute to financial insecurity.24
In addition to financial pressures, patients cite multiple social factors as reasons for
deferring therapy. These include family obligations, lack of social support, social rejection,
and stigmatization.23-25 More than half of HCV patients report feeling stigmatized,
primarily due to the association between HCV and HIV, promiscuity, and/or substance
abuse.25,26 These patients have higher levels of anxiety, worsened quality of life, and
difficulty coping.26 Furthermore, patients may feel stigmatized by their physicians,27 further
reducing the likelihood of treatment adherence.
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For those patients who present for evaluation, fears related to antiviral therapy figure
prominently into their decision to pursue treatment. An important consideration among HCV
patients is the risk to benefit tradeoff related to treatment.24 Though a desire to eradicate a
chronic, progressive infection may seem intuitive, patients may be unable to look beyond the
short-term risks of therapy, particularly side effects. Among patients deferring HCV therapy,
nearly two-thirds cite a fear of side effects, coupled with the asymptomatic nature of their
disease, as the primary reason for deferral.21 These findings are supported by an
international study of treating physicians, who rated patients’ fear of side effects as the most
important barrier to HCV treatment.28 Similar findings were noted in a survey of UK
physicians.20
Fears of treatment-related side effects are not without merit. Virtually all patients will
experience a treatment-related side effect, ranging from mild constitutional symptoms to
significant hematologic abnormalities.2-5 Adverse effects greatly impact quality of life and
may lead to dose reductions and treatment discontinuation. While these fears are valid, they
may also be heightened by the availability of inaccurate or skewed information.29 Therefore,
it is imperative that patients receive appropriate pre-treatment education and counseling to
allay such fears. In addition to side effects, patients express concerns regarding treatment
duration and effectiveness.19-21
Psychiatric Disease
Psychiatric illness represents a significant barrier to HCV treatment. Adverse psychiatric
effects, including irritability, depression, and mood swings, are common complications of
IFN use. Between 21% and 58% of patients will develop significant depression with IFN
therapy.30 Furthermore, HCV-infected patients have a higher prevalence of preexisting
psychiatric illness.31 Recognizing the risks of IFN, clinicians frequently defer therapy for
patients with underlying psychiatric illness.7 Unfortunately, these patients are unlikely to
obtain treatment after initial deferral.32 However, the presence of psychiatric illness is no
longer considered an absolute contraindication to therapy.30 When treated with a
multidisciplinary approach, including regular psychiatric monitoring, patients with
psychiatric disorders can achieve comparable outcomes to those without psychiatric
illness.33 In a randomized, controlled trial, participants initially deferred from therapy due to
substance abuse or psychiatric illness were more likely to become eligible for subsequent
antiviral therapy after enrollment in a multidisciplinary intervention compared to those
receiving standard of care 34.
Injection Drug Use
Injection drug use is a frequent mode of HCV acquisition, accounting for a high proportion
of new cases worldwide, and 60% of incidence cases in the United States.30,35 Active use of
injection drugs is a common reason for HCV treatment deferral.18,36,37 One reason is the
high prevalence of depression and psychiatric illness among intravenous drug users
(IDUs).38 Additionally, concerns regarding poor patient adherence, increased risk of adverse
effects, and post-treatment reinfection may lead to deferral.39 Intravenous drug users have
poor awareness of current treatments, with fewer than half recognizing that HCV is a
curable disease.40,41 However, between 70% and 80% of IDUs express a willingness for
treatment.40-42 Furthermore, favorable treatment outcomes have been demonstrated in both
active IDUs and those receiving methadone maintenance.33,43,44 Therefore, treatment for
these patients should be considered in the setting of close monitoring and adjunctive
psychiatric and substance use counseling.30
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Barriers to hepatitis C treatment may arise at the provider level, including primary care
physicians and subspecialists. Key barriers to treatment include lack of knowledge and
awareness, limited specialist availability and/or lack of referral, and communication issues.
Knowledge and Awareness
Healthcare professionals have demonstrated key knowledge deficits related to HCV
prevalence, risk factors, prevention, and management.12 Among primary care providers, this
may be attributable to a lack of experience. In a nationwide survey of primary care
physicians, 73% of respondents reported seeing 5 or fewer HCV patients in the preceding
year, with 44% reporting no experience with HCV treatment.45 Though most physicians
correctly identified risk factors for HCV, only 59% reported regularly screening for these
risk factors. Similar deficiencies in HCV testing have been noted in studies of family
practitioners and obstetrics and gynecology providers.46,47 Knowledge of HCV was likewise
inadequate among drug-treatment providers.48 Among patients with HCV, perceived
physician incompetence is a known barrier to care.27
Specialist Referral and Availability
Primary care physicians infrequently refer HCV patients for subspecialty evaluation. Only
one-half of HCV-infected patients are referred to a specialist for evaluation and
management.6,49 For patients with normal liver tests, the likelihood of referral is below
30%.45 Furthermore, for those patients referred for treatment, the availability of specialists
presents an additional barrier. It is estimated that 80% of chronic HCV patients are managed
by 20% of gastroenterologists.8 Specialists are concentrated within academic medical
centers or government-designated Centers of Excellence, limiting the availability of local
treatment providers. As a result, patients may face long-distance travel, extended wait times,
and a lack of scheduling flexibility.20,50 While academic hepatologists may be more adept at
managing adverse effects and limiting dose reductions, the number of patients with chronic
HCV may exceed their availability.8 Efforts to expand the availability of specialist expertise
via telemedicine have shown promise.51
Communication Issues
Negative interactions with HCV treatment providers may serve as an additional barrier to
treatment. In a cross-sectional study of 322 HCV patients treated at a tertiary care center,
41% reported communication difficulties with their physicians.27 Specifically, patients felt
rushed, misled, or not listened to. Patients may question a physician’s competence, or feel
stigmatized by these interactions. Healthcare workers are known to harbor negative views of
injection drug users, characterizing them as manipulative and unpleasant.12 As a result of
these interactions, patients may feel discouraged, less likely to listen to physician
recommendations, and more inclined to defer therapy.
Government and Payer Barriers
Governments and payers are critical to delivering HCV services, implementing surveillance
programs, disseminating information, and increasing public and provider awareness. Though
patient and provider factors receive the greatest attention, obstacles arising at the
government and payer level are likewise important. In an international study of HCV
providers, lack of treatment promotion and insufficient funding were noted as significant
government level barriers.28 Likewise, lack of insurance coverage, high out-of-pocket
expenses, and excessive paperwork were cited as payer-level barriers. In a separate study of
UK physicians, more than two-thirds of respondents reported inadequate funding as a barrier
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to quality HCV care.20 These sentiments were echoed in the recent Institute of Medicine
report on the prevention and control of viral hepatitis in the United States.12 Specifically, the
committee noted the poorly developed surveillance system, inadequate educational
initiatives, and fragmented viral hepatitis services in this country. To address these issues,
increased resource allocation and improved collaboration between government, healthcare,
and educational stakeholders are needed. In the European Union, government sponsored
screening and surveillance programs have greatly increased diagnosis rates of HCV
infection 10,11.
Looking forward: Direct Acting Antivirals
The recent introduction of the direct acting antivirals (DAA) boceprevir and teleprevir has
changed the current treatment paradigm for patients with genotype 1 infection. Among
treatment-naïve patients, overall SVR rates exceeding 70% are now possible, with the added
potential for abbreviated treatment duration.4,5 For patients concerned about efficacy and
duration, the introduction of these agents may increase treatment appeal. However, these
benefits must be balanced against increased treatment complexity, higher rates of adverse
events, and the potential for drug-drug interactions.52 It remains to be seen how the
availability of triple therapy will influence current treatment barriers.
Conclusions
Multiple barriers to the diagnosis, evaluation, and delivery of hepatitis C treatment serve to
limit the widespread uptake of antiviral therapy. Though recent advances in HCV treatment
offer the potential for high cure rates and shorter treatment durations, long-standing
obstacles to treatment must be addressed. Poor awareness, misguided and exaggerated fears,
relative contraindications, and insufficient funding all contribute to strikingly low treatment
rates. Recognizing the global burden of infection, there is a critical need to reduce current
barriers to hepatitis C treatment.
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Table
HCV Treatment Rates in Clinical Practice
Author Year Cohort/Setting # Of Patients Treatment Rate (%)
Grebely6 2009 Community-based inner city cohort 1,360 1.1
Butt53 2010 VA National Patient Database 134,934 11.9
Cawthorne17 2002 St. Louis VA 557 13.8
Rocca37 2004 Olmstead County Hepatitis C Registry 366 15.0
Bini54 2005 24 VA medical centers 4,084 17.7
Groom18 2008 Minneapolis VA 520 23.8
Evon32 2007 Academic medical center 433 25.2
Morrill36 2005 Primary care clinic 208 27.4
Falck-Ytter19 2002 Teaching county hospital 293 28.3
Butt16 2005 Pittsburgh VA 354 29.4
Rowan7 2004 Houston VA 580 30.0
VA, Veterans Administration
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